BCRX Q3 2017 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+12.8% YoY

Gross Profit

$8M85.7% margin

Operating Income

-$13M-152.4% margin

Net Income

-$15M-172.8% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+182.7%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$191M

Total Liabilities

$91M

Stockholders' Equity

$101M

Cash & Equivalents

$118M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$8M	+12.8%
Gross Profit	$8M	$8M	-1.5%
Operating Income	-$13M	-$9M	-44.5%
Net Income	-$15M	-$12M	-31.3%

Revenue Segments

Supplemental NDA for RAPIVAB

$5.0B71%

RAPIVAB

$2.0B29%